Comparing the current results to its competitors, Pulse Biosciences Inc reported Revenue increase in the 1 quarter 2026 by 0 % year on year. The revenue growth was below Pulse Biosciences Inc 's competitors' average revenue growth of 5.57 %, achieved in the same quarter.
Pulse Biosciences Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 2.38 %
Pulse Biosciences Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment with established medical device firms specializing in cardiology, oncology, and minimally invasive procedures. Key competitors include Abbott Laboratories, AtriCure, Inc., Boston Scientific Corporation, Johnson & Johnson (Biosense Webster), and Medtronic plc. These competitors possess greater financial, technical, research, manufacturing, marketing, sales, and support capabilities. The company also competes with traditional surgical methods and providers of thermal ablation technologies such as radiofrequency ablation (RFA) and microwave ablation (MWA). The company's NPS technology is designed to offer a less traumatic alternative with reduced collateral damage compared to existing technologies.
September 2, 2025
In the dynamic landscape of medical innovation, Pulse Biosciences, Inc. (Nasdaq: PLSE) has emerged as a pioneer, recently announcing significant advancements in the treatment of benign thyroid nodules (BTNs) through its groundbreaking Nanosecond Pulsed Field Ablation (nsPFA) technology. Based in Hayward, California, Pulse Biosciences is leveraging its proprietary techniques to not only enhance patient care but also illuminate new possibilities in the realm of bioelectric medicine.In a noteworthy step forward, the company has successfully conducted the first procedures in its multicenter clinical study, dubbed PRECISE-BTN. This study aims to evaluate the effectiveness and safety of Pulse Biosciences nsPFA Pe...
May 9, 2024
California-based leading bioelectronics company, Pulse Biosciences, Inc. (PLSE), recently announced the successful completion of its first U.S. procedure using the CellFX nsPFA Percutaneous Electrode System, a significant medical milestone that follows the system s clearance by the Food and Drug Administration (FDA). Pulse Biosciences is known for developing and harnessing the novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology. The CellFX nsPFA Percutaneous Electrode System, a result of this state-of-the-art technology, was utilized in a pioneering procedure. This development symbolizes a major step forward in the biosciences medical industry and various clinical applications. T...
Venus Concept Inc's business model focuses on offering innovative and effective medical aesthetic devices and technology solutions to healthcare professionals.
Iridex Corp's business model revolves around providing advanced medical devices and solutions for the treatment of eye conditions, primarily focused on ophthalmology.
Inmode Ltd is a medical technology company that specializes in developing and commercializing minimally invasive aesthetic and medical solutions. They primarily operate on a direct-to-consumer model, selling their devices to physicians, medical spas, and clinics. In addition to device sales, they generate recurring revenue through consumable product sales and service contracts for their devices.
Hologic Incs business model focuses on developing and commercializing medical technologies and diagnostic products, primarily dedicated to womens healthcare. Their offerings include innovative solutions for breast and skeletal health, gynecological health, and surgical products, aiming to improve patient outcomes and enhance healthcare practices.
Guided Therapeutics Inc operates on a business model focused on developing and commercializing medical devices for the early detection and monitoring of diseases, with a particular emphasis on cervical cancer.
Sources:
Pulse Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Pulse Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
